Sexual Functioning Study With Antidepressants
Sexual Functioning Study With Antidepressants
Effects of two depression medication on sexual functioning
A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active
 controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion
 Hydrochloride Extended-release (WELLBUTRIN XL, 150-450 mg/day) and Extended-release
 Venlafaxine (EFFEXOR XR, 75-225 mg/day) in Subjects with Major Depressive Disorder
Inclusion criteria:

 -  Primary diagnosis of Major Depressive Disorder (MDD)

 -  must have met DSM-IV criteria for current major depressive episode for at least 8
 weeks but no long than 2 years.

 -  HAM-D17 total score of >17 at screening and baseline.

 -  Severity of illness score of >4 at screening and baseline.

 -  Willing to discuss sexual functioning with investigator or designee.

 -  Sexual activity that leads to orgasm at least every 2 weeks.

 Exclusion Criteria:

 -  Past or current DSM-IV diagnosis of Bipolar Disorder I or II, schizophrenia or another
 psychotic disorder(s).

 -  Primary DSM-IV diagnosis or received treatment for Panic Disorder, Obsessive
 Compulsive Disorder or Post Stress Disorder within previous 12 months.

 -  Poses a homicidal or serious suicidal risk, have made an attempt within months prior
 to screening or who has ever been homicidal.

 -  Myocardial infarction with 1 year of screening.

 -  Taken ibupropion hydrochloride or venlafaxine in the last 6 months.

 -  Positive urine test for illicit drug use or alcohol or substance abuse within the past
 12 months.

 -  Psychotherapy within 3 months.

 -  Pregnant.

 -  Electroconvulsive therapy or transcranial magnetic stimulation within 6 months prior
 of screening.

 -  ECG or clinical evidence of atrial or ventricular hypertrophy.